Additional file 2: Table S2. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

Open link

Publication date

February 2018

DOI

10.6084/m9.figshare.6026273.v1

Abstract

Summary of results at Week 24 from included trials among biologic-naĂŻve population. (DOCX 36Â kb

Extracted data

We use cookies to provide a better user experience.

Data Protection

Additional file 2: Table S2. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

Open link

Publication date

February 2018

DOI

10.6084/m9.figshare.6026273.v1

Abstract

Summary of results at Week 24 from included trials among biologic-naĂŻve population. (DOCX 36Â kb

Extracted data

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 2: Table S1. of Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials

Xiaojie Wang (166442)
Hong Zheng (151877)
Tao Shou (3877126)
Chunming Tang (3877123)
Kun Miao (488177)
Ping Wang (42415)

March 2017

The league table of the network for the progression-free survival estimates the treatments according...

Additional file 1: of Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Arthur Kavanaugh (2683)
Dafna Gladman (235996)
Christopher Edwards (1417978)
Georg Schett (895)
Benoit Guerette (6691754)
Nikolay Delev (6691757)
Lichen Teng (6691760)
Maria Paris (6691763)
Philip Mease (77706)

May 2019

Figure S1. PASI-75 response in PsA patients receiving apremilast 30 mg twice daily up to 260 weeks. ...

Additional file 1: Table S1. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

Summary of results at Week 24 from included trials for the overall population. (DOCX 40Â kb

Additional file 4: Table S3. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

ACR response rates and NNT at Week 24 among biologic-naĂŻve population. (DOCX 13Â kb

Additional file 5: Table S4. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

PASI response rates and NNT at Week 24 among biologic-naĂŻve population1. (DOCX 12Â kb

Additional file 8: Table S6. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

Incremental cost per responder over 24Â weeks among biologic-naĂŻve population. (DOCX 13Â kb

Additional file 7: Table S5. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

Incremental cost per responder over 24Â weeks among the overall PsA population. (DOCX 13Â kb

Additional file 6: Figure S2. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

Incremental cost per responder over 24 weeks among the biologic-naïve population. (A) Incremental co...

Additional file 1: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S1. Adjusted mean change from baseline in SF-36 individual domains at weeks 16 (all patients) ...

Additional file 2: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S2. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 2: of Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Philip Helliwell (3424259)
Laura Coates (5622944)
Oliver FitzGerald (26005)
Peter Nash (473901)
Enrique Soriano (5907356)
M. Elaine Husni (5005829)
Ming-Ann Hsu (3086382)
Keith Kanik (3475454)
Thijs Hendrikx (5855157)
Joseph Wu (655119)
Elizabeth Kudlacz (5907371)

October 2018

Table S2. Change from baseline in composite endpoint scores by minimal disease activity (MDA) respon...

Additional file 1: of Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study

Eleni Kampylafka (5566949)
Isabelle dâOliveira (5566964)
Christina Linz (5566955)
Veronika Lerchen (5566958)
Fabian Stemmler (3741502)
David Simon (2658628)
Matthias Englbrecht (825258)
Michael Sticherling (5566961)
JĂźrgen Rech (3741529)
Arnd Kleyer (3741520)
Georg Schett (895)
Axel Hueber (3741514)

July 2018

Figure S1. Examples of baseline and follow-up MRI and HR-pQCT images. Figure S2. Single patient anal...

Additional file 1: of Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Philip Helliwell (3424259)
Laura Coates (5622944)
Oliver FitzGerald (26005)
Peter Nash (473901)
Enrique Soriano (5907356)
M. Elaine Husni (5005829)
Ming-Ann Hsu (3086382)
Keith Kanik (3475454)
Thijs Hendrikx (5855157)
Joseph Wu (655119)
Elizabeth Kudlacz (5907371)

October 2018

Table S1. Least squares (LS) mean change from baseline in composite endpoint scores (full analysis s...

Additional file 1: of Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Peter Nash (473901)
Philip Mease (77706)
Iain McInnes (2063845)
Proton Rahman (192262)
Christopher Ritchlin (4969024)
Ricardo Blanco (118684)
Eva Dokoupilova (4716294)
Mats Andersson (94832)
Radhika Kajekar (4969027)
Shephard Mpofu (4910521)
Luminita Pricop (4716303)

March 2018

Figure S1. Showing study design, Table S1. Presenting independent ethics committees (IECs) or instit...

Additional file 3: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 2: Table S1. of Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials

Xiaojie Wang (166442)
Hong Zheng (151877)
Tao Shou (3877126)
Chunming Tang (3877123)
Kun Miao (488177)
Ping Wang (42415)

March 2017

The league table of the network for the progression-free survival estimates the treatments according...

Additional file 1: of Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Arthur Kavanaugh (2683)
Dafna Gladman (235996)
Christopher Edwards (1417978)
Georg Schett (895)
Benoit Guerette (6691754)
Nikolay Delev (6691757)
Lichen Teng (6691760)
Maria Paris (6691763)
Philip Mease (77706)

May 2019

Figure S1. PASI-75 response in PsA patients receiving apremilast 30 mg twice daily up to 260 weeks. ...

Additional file 1: Table S1. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

Summary of results at Week 24 from included trials for the overall population. (DOCX 40Â kb

Additional file 4: Table S3. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

ACR response rates and NNT at Week 24 among biologic-naĂŻve population. (DOCX 13Â kb

Additional file 5: Table S4. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

PASI response rates and NNT at Week 24 among biologic-naĂŻve population1. (DOCX 12Â kb

Additional file 8: Table S6. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

Incremental cost per responder over 24Â weeks among biologic-naĂŻve population. (DOCX 13Â kb

Additional file 7: Table S5. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

Incremental cost per responder over 24Â weeks among the overall PsA population. (DOCX 13Â kb

Additional file 6: Figure S2. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Vibeke Strand (410780)
M. Elaine Husni (5005829)
Keith Betts (5005826)
Yan Song (119387)
Rakesh Singh (499703)
Jenny Griffith (5005823)
Marci Beppu (5005832)
Jing Zhao (21160)
Arijit Ganguli (3071136)

February 2018

Incremental cost per responder over 24 weeks among the biologic-naïve population. (A) Incremental co...

Additional file 1: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S1. Adjusted mean change from baseline in SF-36 individual domains at weeks 16 (all patients) ...

Additional file 2: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S2. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 2: of Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Philip Helliwell (3424259)
Laura Coates (5622944)
Oliver FitzGerald (26005)
Peter Nash (473901)
Enrique Soriano (5907356)
M. Elaine Husni (5005829)
Ming-Ann Hsu (3086382)
Keith Kanik (3475454)
Thijs Hendrikx (5855157)
Joseph Wu (655119)
Elizabeth Kudlacz (5907371)

October 2018

Table S2. Change from baseline in composite endpoint scores by minimal disease activity (MDA) respon...

Eleni Kampylafka (5566949)
Isabelle dâOliveira (5566964)
Christina Linz (5566955)
Veronika Lerchen (5566958)
Fabian Stemmler (3741502)
David Simon (2658628)
Matthias Englbrecht (825258)
Michael Sticherling (5566961)
JĂźrgen Rech (3741529)
Arnd Kleyer (3741520)
Georg Schett (895)
Axel Hueber (3741514)

July 2018

Figure S1. Examples of baseline and follow-up MRI and HR-pQCT images. Figure S2. Single patient anal...

Additional file 1: of Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Philip Helliwell (3424259)
Laura Coates (5622944)
Oliver FitzGerald (26005)
Peter Nash (473901)
Enrique Soriano (5907356)
M. Elaine Husni (5005829)
Ming-Ann Hsu (3086382)
Keith Kanik (3475454)
Thijs Hendrikx (5855157)
Joseph Wu (655119)
Elizabeth Kudlacz (5907371)

October 2018

Table S1. Least squares (LS) mean change from baseline in composite endpoint scores (full analysis s...

Additional file 1: of Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Peter Nash (473901)
Philip Mease (77706)
Iain McInnes (2063845)
Proton Rahman (192262)
Christopher Ritchlin (4969024)
Ricardo Blanco (118684)
Eva Dokoupilova (4716294)
Mats Andersson (94832)
Radhika Kajekar (4969027)
Shephard Mpofu (4910521)
Luminita Pricop (4716303)

March 2018

Figure S1. Showing study design, Table S1. Presenting independent ethics committees (IECs) or instit...

Additional file 3: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 2: Table S1. of Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials

Xiaojie Wang (166442)
Hong Zheng (151877)
Tao Shou (3877126)
Chunming Tang (3877123)
Kun Miao (488177)
Ping Wang (42415)

March 2017

The league table of the network for the progression-free survival estimates the treatments according...

Additional file 1: of Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Arthur Kavanaugh (2683)
Dafna Gladman (235996)
Christopher Edwards (1417978)
Georg Schett (895)
Benoit Guerette (6691754)
Nikolay Delev (6691757)
Lichen Teng (6691760)
Maria Paris (6691763)
Philip Mease (77706)

May 2019

Figure S1. PASI-75 response in PsA patients receiving apremilast 30 mg twice daily up to 260 weeks. ...

Additional file 2: Table S2. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Abstract

Extracted data

Additional file 2: Table S2. of Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Abstract

Extracted data

Related items

Related items